Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (71-80 of 868) with videos related to

Pageof 87
Sort By:
Journal of the National Cancer Institute|June 30, 2012
Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?Anuj Mahindra, Kenneth C Anderson
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2009
Epigenetic modulation in hematologic malignancies: challenges and progressConstantine S Mitsiades, Kenneth C Anderson
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Bortezomib: a novel therapy approved for multiple myelomaPaul G Richardson, Kenneth C Anderson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease in multiple myelomaNikhil C Munshi, Kenneth C Anderson
Oncotarget|September 20, 2012
Bruton's tyrosine kinase: oncotarget in myelomaYu-Tzu Tai, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
New strategies in the treatment of multiple myelomaNikhil C Munshi, Kenneth C Anderson
Molecular Cancer Therapeutics|January 9, 2003
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discoveryKenneth C Anderson, William S Dalton
Blood|July 23, 2016
A new era of immune therapy in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Seminars in Oncology|February 19, 2005
Role of liposomal anthracyclines in the treatment of multiple myelomaMohamad A Hussein, Kenneth C Anderson
Annual Review of Pathology|January 26, 2011
Pathogenesis of myelomaKenneth C Anderson, Ruben D Carrasco
Pageof 87

Showing results (71-80 of 868) with videos related to

Sort By:
Pageof 87
Journal of the National Cancer Institute|June 30, 2012
Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?Anuj Mahindra, Kenneth C Anderson
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2009
Epigenetic modulation in hematologic malignancies: challenges and progressConstantine S Mitsiades, Kenneth C Anderson
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Bortezomib: a novel therapy approved for multiple myelomaPaul G Richardson, Kenneth C Anderson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease in multiple myelomaNikhil C Munshi, Kenneth C Anderson
Oncotarget|September 20, 2012
Bruton's tyrosine kinase: oncotarget in myelomaYu-Tzu Tai, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
New strategies in the treatment of multiple myelomaNikhil C Munshi, Kenneth C Anderson
Molecular Cancer Therapeutics|January 9, 2003
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discoveryKenneth C Anderson, William S Dalton
Blood|July 23, 2016
A new era of immune therapy in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Seminars in Oncology|February 19, 2005
Role of liposomal anthracyclines in the treatment of multiple myelomaMohamad A Hussein, Kenneth C Anderson
Annual Review of Pathology|January 26, 2011
Pathogenesis of myelomaKenneth C Anderson, Ruben D Carrasco
Pageof 87